Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Show more

Location: 110 Allen Road, Basking Ridge, NJ, 07920, United States | Website: https://www.lisata.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

23.3M

52 Wk Range

$1.87 - $4.20

Previous Close

$2.74

Open

$2.60

Volume

10,198

Day Range

$2.55 - $2.75

Enterprise Value

-1.068M

Cash

25.83M

Avg Qtr Burn

-4.433M

Insider Ownership

20.18%

Institutional Own.

9.11%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LSTA12 (HONEDRA®) Details
Critical limb ischemia

Phase 3

Update

Phase 2b

Data readout

LSTA1 + temozolomide Details
Cancer, Glioblastoma, Glioma

Phase 2a

Data readout

Phase 2a

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details
Pancreatic cancer, Colorectal cancer

Phase 1/2

Data readout

LSTA1 + nivolumab/FOLFIRINOX, Details
Cancer, Gastroesophageal adenocarcinomas

Phase 1/2

Update

Phase 1/2

Initiation

Failed

Discontinued

XOWNA (CLBS16) Details
Coronary Microvascular Dysfunction

Failed

Discontinued

LSTA201 (CLBS201) Details
Chronic kidney disease

Failed

Discontinued